Navigation Links
Lilly and Amylin Set Date and Time for Conference Call
Date:8/25/2008

Companies Will Discuss Recent FDA Advisory Regarding Byetta

INDIANAPOLIS, Aug. 25 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will host a conference call on Tuesday, August 26, 2008 at 5:00 p.m. EDT to discuss the recent FDA advisory on Byetta(R) (exenatide) injection. Participating in the call for Lilly will be Donald Therasse, M.D., vice president of global patient safety. Participating in the call for Amylin will be Daniel M. Bradbury, Amylin's president and chief executive officer, and Orville G. Kolterman, M.D., senior vice president of research and development.

Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at http://www.lilly.com or Amylin's website at http://www.amylin.com The webcast of the conference call will be available for replay through September 26, 2008. For those without access to the Internet, the live call may be accessed by phone by calling (866) 814-1915 (domestic) or (703) 639-1359 (international), passcode 1277182. A replay of the call will also be available by phone through September 26, 2008 beginning approximately one hour after the close of the call and can be accessed at (888) 266-2081 (domestic) or (703) 925-2533 (international), passcode 1277182.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. P-LLY

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help health care professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit http://www.lillydiabetes.com.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... to Moorwick”: the adventures of a young Scottish girl yearning to see the world. ... mother of five who used her time waiting for children to finish their extracurricular activities ... It was a way to give some meaning to the hours I waited for ...
(Date:9/20/2017)... ... 2017 , ... “Monique”: is the story of Monique, whose mother’s deteriorating ... published author, Colleen Crispi, has owned four beauty salons and written a book regarding ... estate and cooking. , “The doctor’s office was only three blocks away, and ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading strategy, ... Flannery, to its strategic advisory and client development team. , In her ... clients across different industries to develop and implement market-justified strategies, modernize and transform ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , ... Innovation Awards (EIA), held this past Thursday night at The Space in Hamden. ... presented their innovative project ideas to a panel of judges for an opportunity ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology: